Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPiReL: DPX-Survivac, Cyclophosphamide, and Pembrolizumab in DLBCL
NCT03349450Phase 2Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Mar 2018
- Primary completion
- Oct 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of maveropepimut-S in diffuse large B-cell lymphoma (DLBCL), sponsored by Sunnybrook Health Sciences Centre. Started Mar 2018; status: completed.
02
Drugs
maveropepimut-S
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03349450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349450.